Mucus clearance and lung function in cystic fibrosis with hypertonic saline by Donaldson, S.H. et al.
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 354;3 www.nejm.org january 19, 2006 241
original article
Mucus Clearance and Lung Function 
in Cystic Fibrosis with Hypertonic Saline
Scott H. Donaldson, M.D., William D. Bennett, Ph.D., Kirby L. Zeman, Ph.D., 
Michael R. Knowles, M.D., Robert Tarran, Ph.D., and Richard C. Boucher, M.D.
From the University of North Carolina at 
Chapel Hill Cystic Fibrosis Research and 
Treatment Center (S.H.D., W.D.B., M.R.K., 
R.T., R.C.B.) and the Center for Environ-
mental Medicine, Asthma and Lung Biol-
ogy (W.D.B., K.L.Z.) — both in Chapel Hill. 
Address reprint requests to Dr. Donaldson 
at 6019 Thurston Bowles Bldg., CB# 7248, 
University of North Carolina at Chapel Hill 
Research and Treatment Center, Chapel Hill, 
NC 27599, or at scott_donaldson@med.
unc.edu.
Drs. Donaldson and Bennett contributed 
equally to this article.
N Engl J Med 2006;354:241-50.
Copyright © 2006 Massachusetts Medical Society.
A BS TR AC T
background
Abnormal homeostasis of the volume of airway surface liquid in patients with cys-
tic fibrosis is thought to produce defects in mucus clearance and airway defense. 
Through osmotic forces, hypertonic saline may increase the volume of airway sur-
face liquid, restore mucus clearance, and improve lung function.
methods
A total of 24 patients with cystic fibrosis were randomly assigned to receive treat-
ment with inhaled hypertonic saline (5 ml of 7 percent sodium chloride) four times 
daily with or without pretreatment with amiloride. Mucus clearance and lung func-
tion were measured during 14-day baseline and treatment periods.
results
Long-term inhalation of hypertonic saline without pretreatment with amiloride (i.e., 
with placebo pretreatment) resulted in a sustained (≥8 hours) increase in 1-hour 
rates of mucus clearance, as compared with those with amiloride pretreatment 
(14.0±2.0 vs. 7.0±1.5 percent, respectively; P = 0.02) and increased 24-hour rates of 
mucus clearance over baseline. Furthermore, inhalation of hypertonic saline with 
placebo improved the forced expiratory volume in one second (FEV
1
) between the base-
line period and the treatment period (mean difference, 6.62 percent; 95 percent 
confidence interval, 1.6 to 11.7; P = 0.02), whereas hypertonic saline with amiloride 
did not improve FEV
1
 (mean difference, 2.9 percent; 95 percent confidence interval, 
−2.2 to 8.0; P = 0.23). Forced vital capacity (FVC), the forced expiratory flow between 
25 and 75 percent of FVC (FEF
25–75
), and respiratory symptoms also significantly im-
proved in patients treated with hypertonic saline and placebo, whereas the residual 
volume as a proportion of total lung capacity (RV:TLC) did not change in either 
group. A comparison of the changes in lung function in the two groups showed no 
significant difference. In vitro data suggested that sustained hydration of airway 
surfaces was responsible for the sustained improvement in mucus clearance, where-
as inhibition of osmotically driven water transport by amiloride accounted for the 
observed loss of clinical benefit.
conclusions
In patients with cystic fibrosis, inhalation of hypertonic saline produced a sustained 
acceleration of mucus clearance and improved lung function. This treatment may 
protect the lung from insults that reduce mucus clearance and produce lung disease.
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Mucus clearance defends the lung against inhaled bacteria. The efficiency of mucus clearance depends on an ade-
quate volume of airway surface liquid (i.e., hydra-
tion).1 One hypothesis for the pathogenesis of 
lung disease in patients with cystic fibrosis is that 
a lack of regulation of sodium absorption and 
chloride secretion causes depletion of airway sur-
face liquid, slows mucus clearance, and promotes 
the formation of adherent mucus plaques on air-
way surfaces. Mucus plaques and plugs obstruct 
airways and provide the nidus for infection.2,3
On the basis of this hypothesis, therapies that 
increase the volume of airway surface liquid, and 
hence mucus clearance, should improve lung dis-
ease in patients with cystic fibrosis. Inhaled hy-
pertonic saline has been shown to produce short-
term stimulation of mucus clearance4,5 and, in 
separate studies, to improve lung function.6,7 In 
vitro studies with normal human airway epithelia 
demonstrated that hypertonic saline increases 
the volume of airway surface liquid, but the ef-
fects were transient and, therefore, predicted to 
be of limited therapeutic benefit.8 These in vitro 
studies, however, demonstrated that slowing the 
absorption of sodium with amiloride, a sodium-
channel blocker, significantly extended the dura-
tion of the increase in the volume of airway 
surface liquid. We tested the hypothesis that 
pretreatment with amiloride would extend the 
duration of hypertonic saline–induced accelera-
tion of mucus clearance and enhance improve-
ment in lung function in patients with cystic 
fibrosis.
me thods
study design
The study protocol was approved by the Univer-
sity of North Carolina Committee on the Protec-
tion of Rights of Human Subjects, and written 
informed consent was obtained. Patients were 
enrolled between January 2001 and February 2004. 
Inclusion criteria included an established diag-
nosis of cystic fibrosis, an age of at least 14 years, 
and a forced expiratory volume in one second 
(FEV
1
) of 50 percent or more of the predicted 
value after bronchodilation. Exclusion criteria in-
cluded unstable lung disease (as evidenced by the 
administration of intravenous antibiotics within 
four weeks before screening, a change of medical 
regimen within two weeks before screening, or 
an FEV
1
 ≥15 percent below the best clinical value 
during the previous six months), evidence of re-
active airways (>15 percent response to broncho-
dilation or clinical diagnosis of asthma), and the 
use of hypertonic saline within two weeks before 
screening. (For details, see the Supplementary 
Appendix, which is available with the full text of 
this article at www.nejm.org.)
After screening, patients with cystic fibrosis 
entered a 14-day baseline observation period 
(Fig. 1), after which they were randomly assigned 
in a 1:1 distribution to pretreatment with either 
amiloride (at a dose of 1 mg per milliliter in 
4.5 ml of 0.12 percent sodium chloride [Sifavitor]) 
or taste-masked placebo (at a dose of 0.25 mg of 
quinine sulfate per milliliter in 4.5 ml of 0.12 
percent sodium chloride [DSM Minera]) before 
the administration of 7 percent sodium chloride 
(at a dose of 5 ml). Aerosols were delivered four 
times daily with the use of a Pari LC Star nebu-
lizer and Pari Proneb Ultra compressor (Pari). 
Albuterol (at a dose of 180 μg) was administered 
with a metered-dose inhaler with a spacer 30 to 
60 minutes before the administration of study 
medications.
study outcomes
The prespecified outcomes of the primary study 
were the percentage changes in FEV
1
 and forced 
vital capacity (FVC) during the treatment period. 
Secondary outcomes were the rates of mucus 
clearance, the forced expiratory flow between 25 
and 75 percent of FVC (FEF
25–75
), the ratio of re-
sidual volume to total lung capacity (RV:TLC), 
and quality of life. The latter was measured with 
the Cystic Fibrosis Questionnaire for teens and 
adults, in which domain scores range from 0 to 
100, with higher scores reflecting better perceived 
health status.9
Whole-lung mucus clearance was measured, 
as previously described,10,11 four times during the 
study: during the baseline interval (basal mucus 
clearance on day 13), immediately after the first 
dose of study medications (mucus clearance af-
ter the first dose on day 15), during long-term use 
of study medication but eight or more hours after 
administration of the preceding dose to assess 
sustained effects (durability of mucus clearance on 
day 26), and immediately after the administra-
tion of study medications at the end of the 
treatment interval (mucus clearance after the last 
dose on day 28). The 1-hour rate of mucus clear-
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ance, calculated from the average of measurements 
at 10-minute intervals, served as the primary index 
of mucociliary clearance. Patients returned 24 
hours after the administration of radioisotopes 
to measure the cumulative mucus clearance.
For comparison, data describing mucus clear-
ance were collected from 15 healthy, nonsmoking 
adults (mean [±SD] age, 25.6±3.9 years; FEV
1
, 
103±9.8 percent of the predicted value) with the 
use of identical techniques, except that healthy 
subjects received pretreatment with normal sa-
line (2.5 ml over a period of 30 minutes, delivered 
by de Vilbiss 646 nebulizer), rather than with alb-
uterol. Neither the administration of albuterol in 
patients with cystic fibrosis nor saline by nebu-
lizer in controls was expected to affect mucus 
clearance.12
Spirometric and plethysmographic measure-
ments of lung volumes were performed accord-
ing to American Thoracic Society standards,13 
and the percentage changes during baseline and 
treatment periods were calculated. Spirometric 
measurement was also performed two hours af-
ter the administration of study medications on 
day 15 and day 28 and compared with values be-
fore administration. Quantitative sputum cultures 
and serum chemical profiles were performed be-
fore and at completion of the treatment period.
In vitro experiments were performed using 
bronchial epithelia obtained and cultured as pre-
viously described.2 Airway surface liquid was la-
beled with 2 mg of Texas red dextran per milli-
liter in 20 μl of phosphate-buffered saline, and 
the volume of airway surface liquid was moni-
tored by axial confocal microscopy.2 Sodium 
chloride (at a dose of 0.8 mg) with or without 
amiloride (final concentration, 400 μM) was 
added (in perfluorocarbon) to the mucosal surface 
of epithelial cultures from patients with cystic 
fibrosis and from controls. The volume of airway 
surface liquid was serially measured before and 
after the addition of sodium chloride. The con-
tribution of chloride transport by the cystic fibro-
sis transmembrane conductance regulator (CFTR) 
to the change in the volume of airway surface 
liquid in normal epithelia after the administra-
tion of sodium chloride was assessed by pretreat-
ing cultures with a CFTR inhibitor (CFTR
inh
-172 
at a concentration of 5 μM)14 or by substituting 
the impermeant anion gluconate for chloride 
(3.0 mg of sodium gluconate with 20 mM of cal-
cium chloride to maintain calcium activity15).
The effect of amiloride on transepithelial 
water transport was measured by the addition of 
mannitol (at a concentration of 300 mM in 100 μl 
of phosphate-buffered saline) with or without 
amiloride (at a concentration of 400 μM) to the 
apical surface of airway epithelial cultures from 
patients with cystic fibrosis to generate an os-
motic driving force. Water flow was quantitated 
by measuring the resulting change in serosal bath 
fluorescence.16 (Additional in vitro methods are 
described in the Supplementary Appendix.)
statistical analysis
Sample size was based on the ability to detect a 
treatment effect equal to 1 SD of the FEV
1
. A sam-
ple size of 16 patients per group provided 80 per-
cent power to detect this treatment effect with 
the use of a two-sided test (α = 0.05). We antici-
pated a reduced variance and an increase in power 
because two FEV
1
 measures were averaged to 
produce each end of interval values.
Univariate data analyses were performed with 
the use of paired or unpaired two-sided t-tests, 
as appropriate, with a P value of 0.05 or less ac-
cepted as indicating significance. Patients who 
had undergone randomization and who had re-
ceived at least one dose of study medication and 
contributed any data during the treatment inter-
val were included in a modified intention-to-treat 
analysis.
For studies of mucus clearance, the ratio of 
particle deposition in central regions of the lung, 
as compared with peripheral regions (C:P ratio), 
was calculated for each mucus-clearance scan. 
The 1-hour and 24-hour mucus-clearance rates 
were calculated and compared with use of paired 
and unpaired t-tests, as appropriate. The effect 
of study treatments on mucus clearance was also 
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Figure 1. Design of the Clinical Study.
QOL denotes quality of life, and MC mucus clearance.
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tested with a mixed-model analysis of three com-
ponents of variance that included the study visit, 
group assignment, and the C:P ratio as explana-
tory variables. Differences that are reported as 
significant were supported by both statistical 
methods.
R esult s
demographic characteristics
Of the 29 patients who underwent screening, 27 
met eligibility criteria and were enrolled. Three 
subjects were withdrawn before randomization 
because of pulmonary exacerbations (two patients) 
or hyperkalemia (one patient). At baseline, the 
treatment groups were well matched (Table 1). 
Three patients who underwent randomization did 
not contribute data to treatment-interval end 
points owing to adverse events and were not in-
cluded in the modified intention-to-treat analysis. 
These events included a pulmonary exacerbation 
(in the group receiving hypertonic saline with 
placebo); probable abdominal sepsis in a patient 
with immunosuppression after liver transplanta-
tion (in the group receiving hypertonic saline with 
amiloride); and an 18.6 percent drop in the FEV
1
 
two hours after the administration of the first 
dose of study drugs (in the group receiving hyper-
tonic saline with amiloride), which was a predefined 
criterion for exclusion. Other adverse events were 
rare or mild in severity (as listed in the Supple-
mentary Appendix).
basal mucus clearance
The mean (±SE) one-hour mucus-clearance rate, 
which is dominated by large-airway clearance, 
did not differ significantly between patients with 
cystic fibrosis (9.3±1.1 percent) and controls 
(10.0±1.7 percent) (mean difference, 0.6; 95 per-
cent confidence interval, −3.3 to 4.7; P = 0.73) (Fig. 
2A and 2B). However, mucus clearance at 24 hours 
was reduced in patients with cystic fibrosis, as 
compared with controls (40.7±2.5 vs. 53.5±2.8 
percent, P<0.001). This difference in the 24-hour 
measure did not reflect altered tracer deposition, 
as the C:P mean (±SE) ratios of particle deposi-
tion did not differ significantly between patients 
with cystic fibrosis (1.48±0.05) and controls (1.57± 
0.06) (mean difference, 0.09; 95 percent confi-
dence interval, −0.07 to 0.25; P = 0.26).
Table 1. Characteristics of the Patients at Baseline.*
Hypertonic Saline
with Amiloride
(N = 12)
Hypertonic Saline
with Placebo
(N = 12)
Male sex — no. of patients 6 4
Age — yr 25±7 27±10
ΔF508 homozygosity — no. of patients (%) 6 (50) 7 (58)
FVC — % of predicted value 90±15 90±13
FEV
1
 — % of predicted value 78±18 78±19
FEF
25–75
 — % of predicted value 59±36 62±41
Concomitant therapies — no. of patients (%)
Recombinant human deoxyribonuclease 4 (33) 4 (33)
Long-term macrolides 3 (25) 3 (25)
Inhaled steroids 6 (50) 6 (50)
Previous use of hypertonic saline 2 (17) 2 (17)
Coexisting illness — no. of patients (%)
Liver disease 2 (17)† 2 (17)
Diabetes 2 (17) 2 (17)
Exocrine pancreatic insufficiency 12 (100) 10 (83)
* Plus–minus values are means ±SD. FVC denotes forced vital capacity, FEV
1
 forced expiratory volume in one second, 
and FEF
25–75
 forced expiratory flow between 25 and 75 percent of FVC.
† Patients underwent liver transplantation.
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effect of hypertonic saline with or without 
amiloride
Baseline 1-hour mucus-clearance rates and cumu-
lative mucus clearance at 24 hours (on day 13) 
did not differ in the two treatment groups (Fig. 2). 
The one-hour mucus-clearance rate that was mea-
sured immediately after the first dose of study 
medications (on day 15) was significantly increased 
relative to baseline in both groups (P = 0.01 and 
P=0.05 in groups receiving hypertonic saline with 
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Figure 2. Effect of Study Medications on Mucus Clearance.
Panel A shows the percentage of particles cleared from the whole lung compartment during the first hour after de-
position in patients with cystic fibrosis who received hypertonic saline after pretreatment with amiloride. Baseline 
mucus clearance (solid inverted triangles), mucus clearance immediately after the first dose of study medications 
(open triangles), and mucus clearance immediately after study medications at the end of the treatment interval (sol-
id circles) in patients with cystic fibrosis are shown in red. Baseline mucus clearance in controls (open black 
squares) is provided for comparison (P≤0.05 for the comparison of basal mucus clearance and clearance after the 
first dose of hypertonic saline and amiloride). Panel B shows the percentage of particles cleared from the whole 
lung compartment during the first hour after deposition in patients with cystic fibrosis who received hypertonic sa-
line after placebo. Baseline mucus clearance (solid inverted triangles), mucus clearance immediately after the first 
dose of study medications (open triangles), and mucus clearance immediately after study medications at the end of 
the treatment interval (solid circles) in patients with cystic fibrosis are shown in blue. Baseline mucus clearance in 
controls (open black squares) is provided for comparison (P≤0.05 for the comparisons between basal mucus clear-
ance and clearance after both the first and last doses of study medications). Panel C shows the sustained effects 
of study medications on mucus clearance, which was measured ≥8 hours after administration on day 26 (open dia-
monds), as compared with baseline (solid triangles) in patients with cystic fibrosis treated with hypertonic saline 
and amiloride (red) or hypertonic saline and placebo (blue) (P≤0.05 for both the comparison of the durable-clear-
ance measurements at the end of the treatment interval between the treatment and control groups and the com-
parison between basal and durable-clearance measures in the group that received hypertonic saline after placebo). 
Panel D shows 24-hour clearance (mean ±SE) measured before study medications (white bars) on study day 
26 after long-term treatment with hypertonic saline and amiloride (red) or hypertonic saline and placebo (blue) 
(P≤0.05 for the comparison between baseline and post-treatment 24-hour clearance values in the group that re -
ceived hypertonic saline with placebo). The 24-hour clearance in controls is shown for comparison, with the mean 
(±SE) plotted as a dotted line and shaded area. 
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amiloride and with placebo, respectively) (Fig. 
2A and 2B). The one-hour mucus-clearance rate 
that was measured immediately after study med-
ications on the final day of treatment (on day 28) 
was similarly increased relative to basal mucus 
clearance, suggesting no diminution in the peak 
effects on mucus clearance over this two-week 
period (Fig. 2A and 2B).
There were two important differences in the 
effects of treatment regimen on mucus clearance 
during long-term administration. First, the assess-
ment of the durability of mucus clearance re-
vealed a significantly faster one-hour mucus-
clearance rate in the group receiving hypertonic 
saline with placebo than in the group receiving 
hypertonic saline with amiloride (14.0±2.0 vs. 
7.0±1.5 percent, P = 0.02) (Fig. 2C). This differ-
ence reflected the fact that only hypertonic sa-
line with placebo produced a sustained increase 
(≥8 hours) in the durability measurement of one-
hour mucus clearance (14.0±2.0 percent) versus 
that for the basal measurement of mucus clear-
ance (9.3±1.6 percent; P = 0.04) (Fig. 2C). Second, 
although the cumulative 24-hour mucus-clear-
ance rate was not significantly higher in the 
group that received hypertonic saline with pla-
cebo at the durability-of-mucus-clearance scan 
(mean difference, 4.6 percent; 95 percent confi-
dence interval, −5.9 to 15.1; P = 0.36), long-term 
administration of hypertonic saline with placebo 
increased the 24-hour rate as compared with pre-
treatment values (P = 0.04), whereas long-term ad-
ministration of hypertonic saline with amiloride 
did not increase the rate (P = 0.49) (Fig. 2D).
lung function
Similar small changes in lung function were ob-
served during the baseline interval in both treat-
ment groups (Fig. 3). The absolute percentage 
changes in lung function during the treatment 
interval favored the group that received hyper-
tonic saline with placebo but were not signifi-
cantly different (mean FEV
1
 difference, 4.7 per-
cent; 95 percent confidence interval, −1.3 to 10.6; 
P = 0.12; mean FVC difference, 1.8 percent; 95 per-
cent confidence interval, −1.9 to 5.5; P = 0.23; 
mean FEF
25–75
 difference, 13.1 percent; 95 per-
cent confidence interval, −1.4 to 27.7; P = 0.07). 
The corresponding absolute increases in FEV
1
 re-
sulting from treatment were 147±39 ml for the 
group receiving hypertonic saline with placebo 
and 34±66 ml for the group receiving hypertonic 
saline with amiloride (mean difference, 113 ml; 
95 percent confidence interval, −44 to 271). 
However, comparisons of changes in lung func-
tion during the treatment and baseline intervals 
revealed significant improvements in FVC (P = 0.05), 
FEV
1
 (P = 0.02), and FEF
25–75
 (P = 0.02) in the group 
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Figure 3. Effect of Study Medications on Lung Function.
The mean (±SE) percentage change in FVC, the FEV
1
, 
and the FEF
25–75
 during the baseline (white bars) and 
treatment intervals are shown for each treatment group, 
indicating the results of administration of hypertonic 
saline with amiloride (red) and with placebo (blue) 
(P<0.05 for comparisons between baseline and post-
treatment measures in the group receiving hypertonic 
saline after placebo). T bars indicate standard errors.
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that received hypertonic saline with placebo but 
no differences in the group that received hyper-
tonic saline with amiloride (P = 0.83, P = 0.23, and 
P = 0.55, respectively) (Fig. 3). No significant dif-
ferences were observed in RV:TLC ratios.
quality of life
The mean (±SE) respiratory symptom score as 
measured after the treatment interval was signifi-
cantly better in the group that received hyper-
tonic saline with placebo than in the group that 
received hypertonic saline with amiloride (82.3±3.1 
vs. 70.0±3.1, P = 0.01). Significant improvement in 
respiratory symptoms but a higher perceived work-
load or burden related to medical treatment was 
also observed in a comparison of scores at base-
line and during treatment in the group that re-
ceived placebo but not in the group that received 
amiloride (complete questionnaire results are avail-
able in the Supplementary Appendix).
safety and adverse events
No treatment-related serious adverse events oc-
curred. Mean (±SE) absolute changes in FEV
1
 two 
hours after the administration of study medica-
tion on day 15 (0.85±3.79 percent in the placebo 
group and –2.47±6.66 percent in the amiloride 
group) and on day 28 (–0.55±4.46 percent in the 
placebo group and –1.39±3.85 percent in the 
amiloride group) were small and not significant-
ly different between groups. Serum chemical anal-
yses, hematologic values, and quantitative sputum 
cultures (for total bacteria and pseudomonas) did 
not change with either treatment (see the Supple-
mentary Appendix).
in vitro response to hypertonic saline
The addition of sodium chloride to the mucosal 
surface of airway epithelial cultures, simulating 
deposition of 7 percent sodium chloride,10 pro-
duced a much larger and more sustained increase 
in the volume of airway surface liquid in airway 
cultures from patients with cystic fibrosis than 
in cultures from controls (Fig. 4A and 4B). We 
tested the hypothesis that the sustained response 
in cultures from patients with cystic fibrosis re-
flected the absence of the CFTR chloride channel 
as a route for transcellular salt absorption. Con-
trol cultures had a significantly increased response 
in the volume of airway surface liquid to hyper-
tonic challenge when pretreated with a CFTR 
chloride-channel blocker (CFTR
inh
-172) or with 
replacement of chloride in the apical hypertonic 
solution with an impermeant anion (Fig. 4B). 
These data indicate that chloride transport through 
CFTR is a key determinant of the response in the 
volume of airway surface liquid to the adminis-
tration of hypertonic saline.
inhibition of transepithelial water 
transport by amiloride
The capacity of hypertonic saline to produce 
large and prolonged increases in the volume of 
airway surface liquid in airway epithelial cultures 
of patients with cystic fibrosis was markedly re-
duced by pretreatment with amiloride (Fig. 4A 
and 4C). The slower increase in serosal fluores-
cence in response to an apical hyperosmolar man-
nitol solution suggested that the reduced response 
in the volume of airway surface liquid to hyper-
tonic saline after amiloride pretreatment reflect-
ed a block of transepithelial water flow (Fig. 4D). 
This effect was not specific to epithelia from pa-
tients with cystic fibrosis, since amiloride also 
slowed osmotically driven water flow in control 
epithelia; the rate of increase in fluorescence was 
reduced by 74.6±4.0 percent in controls, as com-
pared with 89.8±2.3 percent in patients with cystic 
fibrosis (P = 0.01).
The action of amiloride to block the water 
permeability of airways was further character-
ized. First, the 50 percent inhibitory concentra-
tion (IC
50
) for amiloride inhibition of water per-
meability was 6 μM, a value that is less potent 
by a factor of 10 than that for inhibition of the 
epithelial sodium channel. Second, a cellular site 
of action was indicated by experiments in which 
a blocker of cellular aquaporins, mercuric chlo-
ride, mimicked the blockade by amiloride of 
hypertonic saline–induced expansion of airway 
surface liquid; amiloride also inhibited hyper-
tonic saline–induced cell shrinkage. Finally, the 
amiloride blockade was pharmacologically spe-
cific, since an analogue that more potently in-
hibits the epithelial sodium channel (benzamil) 
was active, whereas an analogue more specific 
for the sodium–hydrogen exchanger (dimethyl-
amiloride) was not (additional in vitro data are 
available in the Supplementary Appendix).
Discussion
Treatment of patients who have cystic fibrosis 
with inhaled hypertonic saline after placebo re-
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sulted in a sustained increase in the one-hour 
mucus-clearance rate and was associated with 
improvements in lung function and respiratory 
symptoms over baseline values. In contrast, pa-
tients who were treated with hypertonic saline 
after amiloride had no sustained increase in mu-
cus clearance and no improvement in lung func-
tion or respiratory symptoms. The relative effec-
tiveness of hypertonic saline treatment alone, as 
compared with the administration of hypertonic 
saline after pretreatment with amiloride, was con-
trary to our hypothesis. These findings raised 
two questions: Why was the effect of hypertonic 
saline on mucus clearance so prolonged in pa-
tients with cystic fibrosis as compared with con-
trols?8 And why did amiloride blunt the ability of 
hypertonic saline to produce sustained increases 
in mucus clearance? We investigated these ques-
tions in airway cultures because a tight linkage 
between the volume of airway surface liquid and 
mucus transport has been demonstrated in this 
model system.1
The administration of hypertonic saline in vi-
tro produced a larger and more sustained increase 
in the volume of airway surface liquid in cul-
tures from patients with cystic fibrosis than in 
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Figure 4. Effects of Hypertonic Saline with or without Amiloride on the Amount of Airway Surface Liquid in Epithelia Cultured from Patients 
with Cystic Fibrosis and Controls.
Panel A shows the amount of airway surface liquid (measured linearly in micrometers by confocal microscopy) before and after the ad-
dition of 0.8 mg of sodium chloride to epithelia from patients with cystic fibrosis. Panel B shows the amount of airway surface liquid in 
the epithelia from controls before and after 0.8 mg of sodium chloride (solid black squares). The effect of pretreatment with CFTR inhib-
itor 172 (open red circles) or chloride substitution with gluconate (solid blue triangles) is also depicted. Asterisks denote a significant 
difference in time points between treatment groups and controls (P<0.05). Panel C shows the amount of airway surface liquid before 
and after the addition of 0.8 mg of sodium chloride to the apical surface of airway epithelial cultures from patients with cystic fibrosis 
pretreated with amiloride. Asterisks denote a significant difference in time points as compared with those in Panel A (P<0.05). Panel D 
shows the change in transepithelial water transport (as measured by serosal bath fluorescence) in response to the addition of mannitol 
to the apical surface of airway epithelial cultures from patients with cystic fibrosis who either had pretreatment with amiloride (open red 
circles) or had no pretreatment (solid black squares). The asterisk denotes a significant difference in the slope of lines fitted through 
data points (P<0.05). The I bars denote means ±SE.
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cultures from controls (Fig. 4A and 4B). The role 
of CFTR in the dissipation of the high luminal 
salt concentration that is generated by hypertonic 
saline deposition was revealed with pharmaco-
logic blockade of CFTR and chloride-replacement 
studies (Fig. 4B). The resulting prolongation of 
an osmotic driving force would draw more water 
onto the airway surface in patients with cystic 
fibrosis, increase the volume of airway surface 
liquid, and produce a sustained increase in mu-
cus clearance.
The effect of amiloride in blunting clinical 
improvements with hypertonic saline might also 
be explained by effects on the volume of airway 
surface liquid. In vitro experiments revealed 
markedly reduced expansion of airway surface 
liquid in response to the administration of hyper-
tonic saline after pretreatment with amiloride 
(Fig. 4C) owing to the blockade of apical mem-
brane water permeability (Fig. 4D and the Sup-
plementary Appendix). As a result, the adminis-
tration of hypertonic saline with amiloride may 
increase the tonicity of airway surface liquid, 
which through electrostatic effects on mucins 
may account for the acute increase in mucus 
clearance.17,18 It also may limit the expansion in 
the volume of airway surface liquid, preventing 
the sustained increase in mucus clearance and 
improvement in lung function observed with hy-
pertonic saline alone.
In another article in this issue of the Journal, 
Elkins et al.19 also observed a modest improve-
ment in lung function with inhaled hypertonic 
saline but observed a striking reduction in pulmo-
nary exacerbations. We propose that hypertonic 
saline produced the sustained airway surface hy-
dration required to clear retained mucus, but its 
efficacy was limited by its failure to reach many 
obstructed airways, as evidenced by the moderate 
resulting increase in FEV
1
.19 In contrast, effective 
delivery of hypertonic saline to relatively nonob-
structed airways produced supranormal 1-hour 
mucus-clearance rates and improved cumulative 
24-hour mucus-clearance rates. We speculate that 
the durable increase in mucus clearance protected 
relatively nonobstructed lung regions from exog-
enous insults (e.g., viral infections20,21) that slow 
mucus clearance and hence promote intrapulmo-
nary spread of bacterial infection or the develop-
ment of new mucus obstruction, thus accounting 
for the large reduction in the exacerbation rate 
observed by Elkins et al.
In summary, inhalation of hypertonic saline 
four times daily provides a modest improvement 
in lung function and respiratory symptoms with-
out substantial adverse events. On the basis of 
studies of airway epithelia in vitro, it appears 
likely that the mechanism of action of hyper-
tonic saline is to provide long-term hydration of 
airway surfaces and promote a sustained increase 
in mucus clearance. This study points to a vital 
therapeutic role for the restoration of hydration 
to airway surfaces in patients with cystic fibrosis 
and suggests that measures of sustained mucus 
clearance may serve as a useful surrogate out-
come for future drug development.
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